-   Training & Support

[Expand/Collapse all sections]Expand all

This document outlines details of the Pharmaceutical Benefits Scheme
(PBS) subsidised trastuzumab and trastuzumab emtansine for patients with
early human epidermal growth factor receptor 2 (HER2) positive breast
cancer (EBC), and lapatinib, pertuzumab, trastuzumab, and trastuzumab
emtansine, for patients with metastatic (Stage IV) HER2 positive breast
cancer (metBC), often referred to as 'late stage breast cancer'.

Breast cancer and listing dates

Breast cancer is listed as early HER2 positive breast cancer and
metastatic (Stage IV) HER2 positive breast cancer.

Listing dates are:

Early HER2 positive Breast Cancer (EBC)

-   trastuzumab - 1 October 2006
-    trastuzumab emtansine - 1 April 2020

Metastatic (Stage IV) HER2 positive BC (metBC)

-   lapatinib - 1 May 2008
-    pertuzumab - 1 July 2015
-    trastuzumab - 1 July 2015
-    trastuzumab emtansine - 1 July 2015

For more information, see Written Authority Required Drugs.

Enquiries

Transfer enquiries about prescription arrangements to the PBS - Complex
Drugs Programs team and choose the option relevant to the condition
treated.

The Resources page contains links to application forms, contact details,
item and restriction codes, the PBS schedule and the Services Australia
website.

Related links

Tier 0 technical support - self-sufficiency

Efficient Funding of Chemotherapy (EFC) changes in Pharmaceutical
Benefits Scheme (PBS)

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA
System)

Processing and National Demand Allocation (PaNDA)

Process telephone Authority approval application

Processing Complex Authority Required Listings

Written Authority Required Drugs

                                   

-   Services Australia ABN 90 794 605 008 
